Cargando…

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab

INTRODUCTION: The objective of this study was to estimate longitudinal changes in disease progression (measured by Alzheimer's disease assessment scale-cognitive 11-item [ADAS-cog/11] scale) after bapineuzumab treatment and to identify covariates (demographics or baseline characteristics) contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samtani, Mahesh N., Xu, Steven X., Russu, Alberto, Adedokun, Omoniyi J., Lu, Ming, Ito, Kaori, Corrigan, Brian, Raje, Sangeeta, Brashear, H. Robert, Styren, Scot, Hu, Chuanpu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975060/ https://www.ncbi.nlm.nih.gov/pubmed/29854935 http://dx.doi.org/10.1016/j.trci.2015.09.001

Ejemplares similares

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials
por: Xu, Steven X., et al.
Publicado: (2015)

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
por: Ivanoiu, Adrian, et al.
Publicado: (2016)

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
por: Vandenberghe, Rik, et al.
Publicado: (2016)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
por: Abushouk, Abdelrahman Ibrahim, et al.
Publicado: (2017)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis
por: Arrighi, H Michael, et al.
Publicado: (2016)

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
por: Miles, Luke A., et al.
Publicado: (2013)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
por: Landen, Jaren W., et al.
Publicado: (2017)

ERRATUM: Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
por: Miles, Luke A., et al.
Publicado: (2013)

Differential medial temporal lobe morphometric predictors of item- and relational-encoded memories in healthy individuals and in individuals with mild cognitive impairment and Alzheimer's disease
por: Gomar, Jesus J., et al.
Publicado: (2017)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease
por: Sousa, Amber, et al.
Publicado: (2015)

Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative
por: Samtani, Mahesh N, et al.
Publicado: (2014)

Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
por: Wittenberg, Raphael, et al.
Publicado: (2019)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease
por: Wang, Chang Yi, et al.
Publicado: (2017)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Accelerating drug development for Alzheimer's disease through the use of data standards
por: Neville, Jon, et al.
Publicado: (2017)

Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment
por: Wang, Guoqiao, et al.
Publicado: (2015)

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
por: Schwarz, Adam J., et al.
Publicado: (2019)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training
por: Teixeira, Camila Vieira Ligo, et al.
Publicado: (2018)

Complementary pre‐screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
por: Boada, Mercè, et al.
Publicado: (2021)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Intranasal rifampicin for Alzheimer's disease prevention
por: Umeda, Tomohiro, et al.
Publicado: (2018)

Estrogen activates Alzheimer's disease genes
por: Ratnakumar, Abhirami, et al.
Publicado: (2019)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia
por: Gault, Laura M., et al.
Publicado: (2015)

Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease
por: Frederiksen, Kristian S., et al.
Publicado: (2019)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Progranulin mutations in clinical and neuropathological Alzheimer's disease
por: Vardarajan, Badri N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a6ksokevfros6sk6idtfimcrc4